Joincare H1 2026 Revenue RMB6.583 Billion Down 16.66%, Net Profit RMB648 Million Down 17.49%
Joincare Pharmaceutical Group (600380) reported first-half 2026 revenue of RMB6.583 billion, down 16.66% year-on-year, and net profit attributable to shareholders of RMB648 million, down 17.49%. Basic earnings per share were RMB0.35. The company attributed the decline to deepening medical insurance cost controls, the normalization of national volume-based procurement, and the cyclical bottom of the API industry. It said its business structure continues to optimize and core competitiveness remains solid.
Joincare (600380) disclosed its interim report on August 24. In the first half of 2026, the company achieved operating revenue of RMB6.583 billion, down 16.66% year-on-year; net profit attributable to shareholders of the listed company was RMB648 million, down 17.49%; basic earnings per share were RMB0.35.
During the reporting period, the company's operating performance came under phased pressure, mainly due to multiple factors including deepening medical insurance cost controls, the normalization of national volume-based procurement, and the cyclical bottom of the API industry. The company said its business structure continues to optimize and its core competitiveness remains solid.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is negative for Pharmaceuticals, with intensity 40/100 and 60% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- negative
- Intensity
- 40
- Confidence
- 60%
- Horizon
- Medium term
Pharmaceutical Chemicals
- Direction
- negative
- Intensity
- 35
- Confidence
- 50%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.